Prohibits healthcare insurers from requiring or conducting a review for prescription medicine used to treat alcohol or opioid use disorder containing Methadone, Burenorphine, or Naltrexone, or approved to mitigate opioid withdrawal symptoms.

Introduced

Jan 21, 2026

Last Action

Feb 3, 2026

Session

RI 2026

AI Summary

Get a plain-English explanation of what this bill does, who it affects, and why it matters.

02/03/2026 Committee recommended measure be held for further study

HB 7478

Previous Bill

SR 2120

Next Bill

→

Talk to us

AN ACT RELATING TO INSURANCE -- BENEFIT DETERMINATION AND UTILIZATION REVIEW ACT

AI Summary

Status

Primary Sponsors